About Contact Us Careers

Q Fever Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 4118
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Q Fever Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Sanofi aventis Groupe
Arix Bioscience plc
Yashica Pharmaceuticals Pvt. Ltd
Basilea Pharmaceutica Ltd.
Merck KGaA
Melinta Therapeutics LLC
Teva Pharmaceutical Ltd.
Bayer AG
Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:

Q Fever Market Size & Share, Forecast Report 2037

In the News

In 2022, Pfizer Inc. and Myovant Science provided an update on MYFEMBREE, a 1 mg medication designed for severe pain management, revealing that the U.S. FDA has extended its review timeline for the drug.
In 2022, Sanofi introduced Foundation S, an initiative dedicated to fostering a healthy and beneficial future for both present and future generations.

Author Credits: Radhika Pawar

Report ID: 4118
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of Q fever is estimated at USD 578.33 million.

Q Fever Market size was over USD 554.3 million in 2024 and is anticipated to cross USD 1.05 billion by 2037, witnessing more than 5.1% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to hold largest revenue share by 2037, due to increasing awareness of infectious diseases, growing demand for enhanced diagnostic facilities, and a higher prevalence of Q fever in the region.

The major players in the market are Pfizer Inc., Arix Bioscience plc, Yashica Pharmaceuticals Pvt. Ltd, Merck KGaA, Melinta Therapeutics LLC, Teva Pharmaceutical Ltd., Bayer AG, and Johnson & Johnson Services, Inc.

Inquiry Before Buying Request Free Sample